Blueprint Medicines (NASDAQ:BPMC) Upgraded by StockNews.com to Hold Rating

StockNews.com upgraded shares of Blueprint Medicines (NASDAQ:BPMC) from a sell rating to a hold rating in a research report released on Saturday morning.

A number of other research firms have also recently commented on BPMC. Stephens reaffirmed an “overweight” rating and set a $140.00 price objective on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Needham & Company LLC reissued a “buy” rating and issued a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday, February 13th. Wells Fargo & Company reduced their target price on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Piper Sandler boosted their target price on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Finally, JMP Securities reissued a “market outperform” rating and issued a $125.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $123.83.

Blueprint Medicines Trading Down 2.2 %

BPMC stock opened at $92.25 on Friday. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The company has a fifty day moving average price of $99.55 and a two-hundred day moving average price of $94.40. Blueprint Medicines has a one year low of $80.42 and a one year high of $121.90. The stock has a market cap of $5.90 billion, a price-to-earnings ratio of -85.42 and a beta of 0.62.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Equities analysts anticipate that Blueprint Medicines will post -1.28 EPS for the current year.

Insiders Place Their Bets

In other Blueprint Medicines news, insider Ariel Hurley sold 1,819 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the transaction, the insider now owns 14,967 shares of the company’s stock, valued at approximately $1,395,822.42. The trade was a 10.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 15,000 shares of the business’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $89.77, for a total value of $1,346,550.00. Following the transaction, the director now directly owns 157,557 shares of the company’s stock, valued at approximately $14,143,891.89. The trade was a 8.69 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 49,851 shares of company stock valued at $4,984,696. 4.21% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Mackenzie Financial Corp increased its stake in shares of Blueprint Medicines by 99.6% in the fourth quarter. Mackenzie Financial Corp now owns 14,177 shares of the biotechnology company’s stock valued at $1,237,000 after buying an additional 7,076 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Blueprint Medicines in the fourth quarter valued at approximately $116,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Blueprint Medicines by 5.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,946 shares of the biotechnology company’s stock valued at $20,928,000 after buying an additional 12,035 shares during the period. Woodline Partners LP increased its stake in shares of Blueprint Medicines by 19.1% in the fourth quarter. Woodline Partners LP now owns 540,192 shares of the biotechnology company’s stock valued at $47,116,000 after buying an additional 86,614 shares during the period. Finally, Zimmer Partners LP increased its stake in shares of Blueprint Medicines by 59.5% in the fourth quarter. Zimmer Partners LP now owns 33,650 shares of the biotechnology company’s stock valued at $2,935,000 after buying an additional 12,550 shares during the period.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.